Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Purpose Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinumbased chemotherapy.
Materials and Methods Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated.
Results A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology.
Conclusion Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.

번역하기

참고문헌 (Reference)

1 Lee SH, "Serum reactive oxygen species modulator 1(Romo1)as a potential diagnostic biomarker for non-small cell lung cancer" 85 : 175-181, 2014

2 Chung YM, "Replicative senescence induced by Romo1-derived reactive oxygen species" 283 : 33763-33771, 2008

3 Lee SH, "Reactive oxygen species modulator 1(Romo1)overexpression is an independent predictor of poor survival in NSCLC patients who undergo surgical resection" 87 : 45-52, 2015

4 Pelicano H, "ROS stress in cancer cells and therapeutic implications" 7 : 97-110, 2004

5 Tsao MS, "Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer" 25 : 5240-5247, 2007

6 Sosa V, "Oxidative stress and cancer : an overview" 12 : 376-390, 2013

7 Chung JS, "Overexpression of Romo1 promotes production of reactive oxygen species and invasiveness of hepatic tumor cells" 143 : 1084-1094, 2012

8 Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)" 45 : 228-247, 2009

9 Miller VA, "Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib" 26 : 1472-1478, 2008

10 Chung JS, "Mitochondrial reactive oxygen species originating from Romo1 exert an important role in normal cell cycle progression by regulating p27(Kip1)expression" 43 : 729-737, 2009